Serum Institute of India Pvt. Ltd.

Serum Institute of India Pvt. Ltd. is the vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization, Geneva and are being used in around 140 countries across the globe in their national immunization programs, saving millions of lives throughout the world.

Serum Institute of India Pvt. Ltd., established in 1996 and headquartered in India, Asia., specializes in Late Stage Venture, Early Stage Venture investments across Biotechnology, Therapeutics, Clinical Trials, Health Diagnostics, Venture Capital, Finance, Business Development, Health Care, Financial Services, Advice. The organization boasts a portfolio of 6 investments, with an average round size of $43.2M and 2 successful exits. Their recent investments include Visterra, Flagship Pioneering, Polaris Partners, Vertex Ventures, Omega Funds. The highest investment round they participated in was $6.9B. Among their most notable exits are Visterra and Flagship Pioneering. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.